Cargando…
Therapeutic strategies of recurrent glioblastoma and its molecular pathways ‘Lock up the beast’
Glioblastoma multiforme (GBM) has a poor prognosis—despite aggressive primary treatment composed of surgery, radiotherapy and chemotherapy, median survival is still around 15 months. It starts to grow again after a year of treatment and eventually nothing is effective at this stage. Recurrent GBM is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929780/ https://www.ncbi.nlm.nih.gov/pubmed/33680090 http://dx.doi.org/10.3332/ecancer.2021.1176 |